We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
-0.04%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$304M
AUM Growth
+$1.15M
(+0.38%)
Cap. Flow
+$57.5M
Cap. Flow
% of AUM
18.92%
Top 10 Holdings %
Top 10 Hldgs %
41.92%
Holding
84
New
27
Increased
13
Reduced
15
Closed
15
Top Buys
| 1 |
Krystal Biotech
KRYS
|
+$7.32M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$4.48M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
+$4.42M |
| 4 |
SLRN
ACELYRIN
SLRN
|
+$4.25M |
| 5 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$3.91M |
Top Sells
| 1 |
AKRO
Akero Therapeutics
AKRO
|
+$11.4M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$8.67M |
| 3 |
APLS
Apellis Pharmaceuticals
APLS
|
+$7.91M |
| 4 |
Amylyx Pharmaceuticals
AMLX
|
+$7.08M |
| 5 |
Vaxcyte
PCVX
|
+$6.91M |
Sector Composition
| 1 | Healthcare | 67.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Taysha Gene Therapies
TSHA
$1.71B
| $4.19M | 1.38% |
+1,325,000
| New | +$2.47M |
|
|
DCPH
27
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $4.13M | 1.36% |
+325,000
| New | +$4.48M |
|
28
Phathom Pharmaceuticals
PHAT
$873M
| $4.1M | 1.35% |
395,000
+240,750
| +156% | +$3.3M |
|
|
RVNC
29
DELISTED
Revance Therapeutics, Inc.
RVNC
| $4.01M | 1.32% |
350,000
-175,000
| -33% | -$3.36M |
|
|
30
Amylyx Pharmaceuticals
AMLX
$1.97B
| $3.94M | 1.29% |
215,000
-335,000
| -61% | -$7.08M |
|
|
CBAY
31
CALL
DELISTED
Cymabay Therapeutics
CBAY
| $3.55M | 1.17% |
+237,900
| New | +$3.15M |
|
32
Xenon Pharmaceuticals
XENE
$6.6B
| $3.38M | 1.11% |
98,951
-86,049
| -47% | -$3.22M |
|
33
PUT
Immunovant
IMVT
$8.27B
| $3.26M | 1.07% |
+85,000
| New | +$1.92M |
|
34
Crinetics Pharmaceuticals
CRNX
$8.88B
| $3.02M | 0.99% |
+101,443
| New | +$2.09M |
|
35
Syndax Pharmaceuticals
SNDX
$2.02B
| $2.9M | 0.96% |
200,000
-150,000
| -43% | -$2.84M |
|
|
IMGN
36
DELISTED
Immunogen Inc
IMGN
| $2.78M | 0.91% |
175,000
+75,000
| +75% | +$1.25M |
|
37
Structure Therapeutics
GPCR
$3.45B
| $2.77M | 0.91% |
+55,000
| New | +$1.77M |
|
|
JBIO
38
Jade Biosciences
JBIO
$1.27B
| $2.73M | 0.9% |
5,748
| – | – |
|
|
MOR
39
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $2.69M | 0.88% |
+400,000
| New | +$3.08M |
|
40
Cytokinetics
CYTK
$10.9B
| $2.65M | 0.87% |
+90,000
| New | +$3M |
|
|
MRTX
41
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $2.61M | 0.86% |
60,000
-140,000
| -70% | -$5M |
|
42
EyePoint Inc
EYPT
$1.12B
| $2.6M | 0.85% |
+325,000
| New | +$3.56M |
|
43
Viking Therapeutics
VKTX
$4.31B
| $2.49M | 0.82% |
225,000
-425,000
| -65% | -$6.08M |
|
|
ATXS
44
DELISTED
Astria Therapeutics
ATXS
| $2.24M | 0.74% |
300,000
-173
| -0.1% | -$1.48K |
|
|
FOLD
45
DELISTED
Amicus Therapeutics
FOLD
| $2.13M | 0.7% |
175,000
-25,000
| -13% | -$322K |
|
|
KRTX
46
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $2.11M | 0.7% |
12,500
| – | – |
|
|
SLRN
47
DELISTED
ACELYRIN
SLRN
| $2.03M | 0.67% |
+200,000
| New | +$4.25M |
|
|
SLRN
48
PUT
DELISTED
ACELYRIN
SLRN
| $2.03M | 0.67% |
+200,000
| New | +$4.25M |
|
49
Zentalis Pharmaceuticals
ZNTL
$364M
| $2.01M | 0.66% |
100,000
| – | – |
|
50
BridgeBio Pharma
BBIO
$15.9B
| $1.98M | 0.65% |
75,000
+33,000
| +79% | +$936K |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Ghost Tree Capital held 84 positions worth $304M, up 0.38% from $303M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Ghost Tree Capital deployed $57.5M of net new capital in Q3 2023, opening 27 new positions and adding to 13 existing holdings. Its largest new stake was Deciphera Pharmaceuticals, Inc. Common Stock: 325,000 shares worth $4.13M.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 91% a quarter earlier.
On the sell side, the largest reduction was Akero Therapeutics, an estimated $11.4M trimmed.
- Ghost Tree Capital's largest Q3 2023 buy was Deciphera Pharmaceuticals, Inc. Common Stock: 325,000 shares worth $4.13M.
- Ghost Tree Capital added most to Krystal Biotech in Q3 2023, an estimated $7.32M increase.
- Ghost Tree Capital's biggest Q3 2023 reduction was Akero Therapeutics, cutting an estimated $11.4M.
- Ghost Tree Capital fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $8.67M.
- Ghost Tree Capital's ten largest holdings make up 42% of its $304M portfolio in Q3 2023.
- Ghost Tree Capital opened 27 new positions and closed 15 in Q3 2023.
- Ghost Tree Capital's portfolio value rose 0.38% quarter-over-quarter to $304M.
Based on Ghost Tree Capital's 13F filing for Q3 2023, filed 14 Nov 2023.